Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Lung
05:21

Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through First and Subsequent Lines of Therapy: 1st vs. 2nd Generation ALK TKIs

FEATURING Perran Fulden Yumuk
  • 89 views
  • March 18, 2021
  • 1
17:12

Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy: 2nd Gen ALK TKIs Alectinib & Brigatinib, and BFAST NGS Screening Workflow

FEATURING Perran Fulden Yumuk
  • 170 views
  • March 18, 2021
  • 2
20:50

Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Treatment Options as 1st and 2nd Line Treatment + TKI Resistance Mechanisms

FEATURING Mustafa Erman
  • 110 views
  • November 12, 2019
08:26

Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and 2nd Line IO Treatment Options + TKI Resistance Mechanisms

FEATURING Mustafa Erman
  • 206 views
  • November 12, 2019
05:02

Xth Eurasian Hematology-Oncology Congress

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in Pretreated Advanced NSCLC

FEATURING Basak Oyan Uluc
  • 121 views
  • November 12, 2019
  • 1
14:47

Xth Eurasian Hematology-Oncology Congress

(DO NOT USE) Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is Treatment w/o Chemo Possible, IO vs. Chemo & IO+Chemo vs. Chemo?

FEATURING Basak Oyan Uluc
  • 187 views
  • November 12, 2019
  • 1
05:57

Xth Eurasian Hematology-Oncology Congress

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced NSCLC & (Relapsed) Extensive Stage SCLC and Their Benefit to OS and PFS

FEATURING Basak Oyan Uluc
  • 181 views
  • November 12, 2019